DTIL (DTIL) counsel logs RSU vesting and tax sell-to-cover share sale

Rhea-AI Filing Summary

PRECISION BIOSCIENCES INC General Counsel and Secretary Dario Scimeca reported RSU vesting and a related tax sale of common stock. On February 17, 2026, 16,667 Restricted Stock Units vested and converted into 16,667 shares of common stock, increasing his direct holdings. Each RSU represents a right to receive one common share.

On February 18, 2026, he sold 4,925 common shares in an open-market transaction at $3.84 per share under a pre-established Rule 10b5-1 trading plan. The sale was a "sell-to-cover" transaction, with shares sold only to cover tax withholding obligations and related fees from the RSU vesting.

Insider Trade Summary

Net Seller: 4,925 shares ($18,912)

Net Sell 3 txns

Insider Scimeca Dario

Role General Counsel and Secretary

Sold 4,925 shs ($19K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,925	$3.84	$19K
Exercise	Restricted Stock Units	16,667	$0.00	--
Exercise	Common Stock	16,667	$0.00	--

Holdings After Transaction: Common Stock — 56,457 shares (Direct); Restricted Stock Units — 33,333 shares (Direct)

Footnotes (1)

1. Represents the vesting of Restricted Stock Units ("RSUs") on February 17, 2026. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The sales were effected pursuant to a Rule 10b5-1 plan adopted on September 29, 2025. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees. RSUs vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scimeca Dario

(Last) (First) (Middle)

C/O PRECISION BIOSCIENCES, INC.

302 E PETTIGREW STREET, SUITE A-100

(Street)

DURHAM NC 27701

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PRECISION BIOSCIENCES INC [ DTIL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel and Secretary

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		M		16,667(1)	A	$0(2)	61,382	D
Common Stock	02/18/2026		S(3)		4,925	D	$3.84	56,457	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	02/17/2026		M			16,667	(4)	(4)	Common Stock	16,667	$0	33,333	D

Explanation of Responses:

1. Represents the vesting of Restricted Stock Units ("RSUs") on February 17, 2026.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. The sales were effected pursuant to a Rule 10b5-1 plan adopted on September 29, 2025. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

4. RSUs vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Remarks:

	/s/ Dario Scimeca	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did DTIL executive Dario Scimeca report on this Form 4?

Dario Scimeca reported RSU vesting and a related tax sale. On February 17, 2026, 16,667 Restricted Stock Units vested and converted into common shares, followed by a February 18, 2026 sale of 4,925 shares solely to cover tax withholding obligations.

How many DTIL shares did Dario Scimeca sell and at what price?

He sold 4,925 shares of Precision BioSciences common stock at $3.84 per share. The transaction was executed under a Rule 10b5-1 trading plan and designated as a sell-to-cover sale for tax withholding and related fees from RSU vesting.

Were Dario Scimeca’s DTIL share sales discretionary or under a Rule 10b5-1 plan?

The sale was effected under a pre-established Rule 10b5-1 trading plan adopted on September 29, 2025. According to the filing, shares were sold only to cover tax withholding obligations and fees tied to the vesting and settlement of RSUs.

What does the RSU vesting reported by DTIL’s General Counsel represent?

The filing states that 16,667 Restricted Stock Units vested on February 17, 2026. Each RSU represents a contingent right to receive one share of Precision BioSciences common stock, so the vesting resulted in the issuance of 16,667 common shares to the reporting person.

How many DTIL Restricted Stock Units does Dario Scimeca hold after this transaction?

After the February 17, 2026 vesting event, the Form 4 reports that Dario Scimeca held 33,333 Restricted Stock Units. These RSUs vest in three substantially equal annual installments beginning on February 17, 2026, subject to his continued service with the company.

Why did Dario Scimeca sell DTIL shares following his RSU vesting?

The filing explains the transaction was a sell-to-cover sale. Shares were sold only to satisfy required tax withholding obligations and related fees from the vesting and settlement of Restricted Stock Units, not for other discretionary selling purposes.